SCHEMBL21995535

SCHEMBL21995535

CCCCCCCCCCCCSc1ncc(-c2ccc(N)nc2)cn1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.49
MEN1 O00255 2/20 0.49
GAA P10253 2/20 0.49
KMT2A Q03164 2/20 0.49
HSD17B10 Q99714 2/20 0.49
TSHR P16473 1/20 0.49
HTT P42858 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
SMN1; SMN2 Q16637 4/20 0.43
ALDH1A1 P00352 3/20 0.43
MAPT P10636 2/20 0.43
HPGD P15428 2/20 0.43
LMNA P02545 1/20 0.43
HASPIN Q8TF76 2/20 0.43
PTGES O14684 2/20 0.41
RAB9A P51151 2/20 0.40
NPC1 O15118 1/20 0.40
NFKB1 P19838 1/20 0.40
NFKB2 Q00653 1/20 0.40
RELA Q04206 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9507636 0.81 NPC1 (0.47) KDM4EMEN1GAAKMT2AHSD17B10
SCHEMBL9224618 0.81 NPC1 (0.47) KDM4EMEN1GAAKMT2AHSD17B10
SCHEMBL8970762 0.81 NPC1 (0.47) KDM4EMEN1GAAKMT2AHSD17B10
SCHEMBL26449578 0.79 KDM4E (0.57) KDM4EMEN1GAAKMT2AHSD17B10
SCHEMBL9510040 0.78 ALDH1A1 (0.50) KDM4EHSD17B10TSHRHTTL3MBTL1
SCHEMBL9506166 0.78 ALDH1A1 (0.50) KDM4EHSD17B10TSHRHTTL3MBTL1
SCHEMBL9506149 0.78 ALDH1A1 (0.50) KDM4EHSD17B10TSHRHTTL3MBTL1
SCHEMBL9507596 0.78 ALDH1A1 (0.50) KDM4EHSD17B10TSHRHTTL3MBTL1
SCHEMBL9506138 0.78 ALDH1A1 (0.50) KDM4EHSD17B10TSHRHTTL3MBTL1
SCHEMBL9506321 0.78 ALDH1A1 (0.50) KDM4EHSD17B10TSHRHTTL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250304558-A1 HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF EPILEPSY OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2025-10-02 US disclosed
US-12391674-B2 Heterocyclic compounds for the treatment of epilepsy OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2025-08-19 US disclosed
US-20210403456-A1 HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF EPILEPSY OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2021-12-30 US disclosed
EP-3887358-A1 HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF EPILEPSY Otsuka Pharmaceutical Co., Ltd. (JP) 2021-10-06 EP disclosed
CN-113166076-A Heterocyclic compounds for the treatment of epilepsy 大塚制药株式会社 2021-07-23 CN disclosed
WO-2020111263-A1 HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF EPILEPSY OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2020-06-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12391674-B2 Heterocyclic compounds for the treatment of epilepsy SLC6A11, SCN1A, SCN1B KDM4E 779/4885MEN1 450/4885GAA 3101/4885
US-20210403456-A1 HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF EPILEPSY SLC6A11, SCN1A, SCN1B KDM4E 779/4885MEN1 450/4885GAA 3101/4885
US-20250304558-A1 HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF EPILEPSY SLC6A11, SCN1A, KCNH1 KDM4E 1095/4885MEN1 402/4885GAA 2594/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.